Figure 3.

Projected costs per woman over time, without and with pre-exposure prophylaxis (PrEP). This figure presents the components of the cumulative costs at 1, 2, 5, 10, and 20 years and over a woman’s lifetime, with No PrEP and PrEP availability. PrEP costs (shaded blue) are divided by their components, including drug costs only, PrEP monitoring costs (chemistry panels), and human immunodeficiency virus (HIV) testing costs. HIV care costs for those who became infected (shaded orange) include the costs for HIV-related care and antiretroviral therapy (ART; shaded red). Costs are scaled per 1000 people and reported in thousands (2010 US dollars).